The primary objective of AREDS2 is to evaluate the effect of dietary xanthophylls (lutein/zeaxanthin) and/or omega-3 LCPUFAs (DHA and EPA) on progression to advanced AMD. This objective will be accomplished by collecting and assessing the data on approximately 4,000 AREDS2 participants aged 50 to 85 years (of which 65 participants are from the NIH center), who at the time of enrollment, have sufficiently clear lenses for quality fundus photographs and have either: 1) bilateral large drusen or 2) large drusen in one eye and advanced AMD (neovascular AMD or central geographic atrophy) in the fellow eye. The objectives of AREDS2 are to: 1. Study the effects of high supplemental doses of the dietary xanthophylls (lutein and zeaxanthin) and omega-3 LCPUFAs (DHA and EPA) on the development of advanced AMD. 2. Study the effects of these supplements on moderate vision loss (doubling of the visual angle or the loss of 15 or more letters on the ETDRS chart). 3. Study the effects of these supplements on cataract. 4. Study the effects of eliminating beta-carotene in the original AREDS formulation on the development and progression of AMD. 5. Study the effects of reducing zinc in the original AREDS formulation on the development and progression of AMD. 6. Validate the fundus photographic AMD scale developed from the Age-Related Eye Disease Study.

Agency
National Institute of Health (NIH)
Institute
National Eye Institute (NEI)
Type
Investigator-Initiated Intramural Research Projects (ZIA)
Project #
1ZIAEY000485-05
Application #
8737653
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
5
Fiscal Year
2013
Total Cost
$141,835
Indirect Cost
Name
U.S. National Eye Institute
Department
Type
DUNS #
City
State
Country
Zip Code
Yiu, Glenn; Chiu, Stephanie J; Petrou, Philip A et al. (2015) Relationship of central choroidal thickness with age-related macular degeneration status. Am J Ophthalmol 159:617-26
Ehler, Martin; Dobrosotskaya, Julia; Cunningham, Denise et al. (2015) Modeling Photo-Bleaching Kinetics to Create High Resolution Maps of Rod Rhodopsin in the Human Retina. PLoS One 10:e0131881
Petrou, Philip A; Cunningham, Denise; Shimel, Katherine et al. (2015) Intravitreal sirolimus for the treatment of geographic atrophy: results of a phase I/II clinical trial. Invest Ophthalmol Vis Sci 56:330-8
Chew, Emily Y (2015) There is level 1 evidence for intensive glycemic control for reducing the progression of diabetic retinopathy in persons with type 2 diabetes. Endocrine 49:1-3
Chew, Emily Y; Klein, Michael L; Clemons, Traci E et al. (2015) Genetic testing in persons with age-related macular degeneration and the use of the AREDS supplements: to test or not to test? Ophthalmology 122:212-5
Chen, Shida; Chew, Emily Y; Chan, Chi-Chao (2015) Pathology characteristics of ocular von Hippel-Lindau disease with neovascularization of the iris and cornea: a case report. J Med Case Rep 9:66
Flamendorf, Jason; Agrón, Elvira; Wong, Wai T et al. (2015) Impairments in Dark Adaptation Are Associated with Age-Related Macular Degeneration Severity and Reticular Pseudodrusen. Ophthalmology 122:2053-62
Chew, Emily Y; Clemons, Traci E; Peto, Tunde et al. (2015) Ciliary neurotrophic factor for macular telangiectasia type 2: results from a phase 1 safety trial. Am J Ophthalmol 159:659-666.e1
Grassmann, Felix; Fleckenstein, Monika; Chew, Emily Y et al. (2015) Clinical and genetic factors associated with progression of geographic atrophy lesions in age-related macular degeneration. PLoS One 10:e0126636
Glaser, Tanya S; Doss, Lauren E; Shih, Grace et al. (2015) The Association of Dietary Lutein plus Zeaxanthin and B Vitamins with Cataracts in the Age-Related Eye Disease Study: AREDS Report No. 37. Ophthalmology 122:1471-9

Showing the most recent 10 out of 58 publications